Immunotherapy & Immuno-Oncology
Part of Healthcare - Oncology
 JNJ | Johnson & Johnson | $0.6t | $257.38 | +0.1% | 4.3M |
 ABBV | ABBVIE INC. | $443.4b | $243.94 | -0.9% | 3.0M |
 MRK | Merck & Co., Inc. | $315.6b | $128.25 | +0.0% | 5.0M |
 AZN | AstraZeneca PLC | $263.1b | $161.34 | -0.1% | 2.2M |
 AMGN | Amgen Inc | $207.9b | $405.69 | -0.7% | 1.9M |
 BMY | Bristol-Myers Squibb Co. | $133.4b | $64.03 | +0.8% | 6.8M |
 REGN | Regeneron Pharmaceuticals Inc | $78.2b | $767.67 | +0.4% | 327.6K |
 RPRX | Royalty Pharma plc Class A Ordinary Shares | $25.3b | $57.29 | -0.9% | 1.8M |
 MRNA | Moderna, Inc. Common Stock | $22.0b | $54.58 | -4.2% | 4.9M |
 IBRX | ImmunityBio, Inc. Common Stock | $7.5b | $7.34 | +0.8% | 7.0M |
 ACLX | Arcellx, Inc. Common Stock | $6.7b | $115.06 | -0.0% | 16.1M |
 CGON | CG Oncology, Inc. Common stock | $6.3b | $74.80 | +3.2% | 800.7K |
 RCUS | Arcus Biosciences, Inc. | $3.5b | $28.34 | +2.3% | 2.5M |
 NKTR | Nektar Therapeutics | $2.4b | $73.90 | +0.5% | 354.1K |
 PGEN | Precigen, Inc. Common Stock | $2.4b | $6.99 | +0.1% | 6.1M |
 SLS | SELLAS Life Sciences Group, Inc. Common Stock | $2.2b | $11.66 | -1.5% | 3.4M |
 IOVA | Iovance Biotherapeutics, Inc. Common Stock | $1.8b | $6.17 | +42.4% | 70.9M |
 BCAX | Bicara Therapeutics Inc. Common Stock | $1.8b | $27.47 | +6.1% | 624.4K |
 SNDX | Syndax Pharmaceuticals, Inc. | $1.7b | $19.97 | -0.8% | 982.4K |
 XNCR | Xencor, Inc. | $1.4b | $20.13 | +1.0% | 842.2K |
 INBX | Inhibrx Biosciences, Inc. Common Stock | $1.2b | $85.28 | +1.5% | 73.7K |
 IMTX | Immatics N.V. Ordinary Shares | $1.2b | $9.43 | -3.6% | 284.0K |
 CRVS | Corvus Pharmaceuticals, Inc. | $1.1b | $13.71 | -0.4% | 468.9K |
 CGEM | Cullinan Therapeutics, Inc. Common Stock | $1.0b | $18.14 | +2.1% | 485.7K |
 REPL | Replimune Group, Inc. | $1.0b | $12.35 | +8.6% | 5.5M |
 JANX | Janux Therapeutics, Inc. Common Stock | $0.9b | $15.52 | +0.5% | 227.6K |
 OMER | Omeros Corporation | $0.9b | $13.09 | +3.9% | 675.2K |
 CADL | Candel Therapeutics, Inc. Common Stock | $0.7b | $10.51 | +1.3% | 1.2M |
 AURA | Aura Biosciences, Inc. Common Stock | $0.7b | $7.70 | +7.7% | 517.5K |
 CTMX | CytomX Therapeutics, Inc. | $0.7b | $3.38 | +0.9% | 1.5M |
 CBIO | Crescent Biopharma, Inc. Common Stock | $0.5b | $16.41 | +4.4% | 116.8K |
 CMPX | Compass Therapeutics, Inc. Common Stock | $344.0m | $1.97 | +5.6% | 6.3M |
 AGEN | Agenus Inc. | $312.3m | $7.58 | -3.9% | 2.3M |
 ALXO | ALX Oncology Holdings Inc. Common Stock | $261.1m | $2.15 | +10.9% | 519.6K |
 MGNX | MacroGenics, Inc. | $242.8m | $4.01 | +2.7% | 536.0K |
 CGEN | Compugen Ltd | $222.3m | $2.31 | +1.3% | 202.7K |
 CHRS | Coherus Oncology, Inc. Common Stock | $217.5m | $1.25 | -12.8% | 3.6M |
 GLSI | Greenwich LifeSciences, Inc. | $198.2m | $14.23 | -0.6% | 82.1K |
 INDP | Indaptus Therapeutics, Inc. Common Stock | $171.9m | $1.29 | -7.5% | 244.8K |
 HURA | TuHURA Biosciences, Inc. Common Stock | $138.2m | $2.12 | +1.0% | 85.0K |
 GNLX | Genelux Corporation Common Stock | $131.8m | $2.75 | +7.2% | 196.9K |
 ANIX | Anixa Biosciences, Inc. | $116.4m | $3.44 | +0.6% | 103.1K |
 CUE | Cue Biopharma, Inc. | $112.7m | $27.55 | +3.3% | 128.7K |
 ONCY | Oncolytics Biotech, Inc. Common Shares | $92.5m | $0.82 | +2.1% | 541.8K |
 MAIA | MAIA Biotechnology, Inc. | $76.0m | $1.41 | +1.4% | 344.3K |
 ELTX | Elicio Therapeutics, Inc. Common Stock | $73.5m | $3.15 | 0.0% | 204.1K |
 XBIT | XBiotech Inc | $68.1m | $2.29 | +0.4% | 9.0K |
 XLO | Xilio Therapeutics, Inc. Common Stock | $59.5m | $9.62 | +1.7% | 23.8K |
 CNTX | Context Therapeutics Inc. Common Stock | $55.1m | $0.49 | -27.0% | 4.1M |
 TIL | Instil Bio, Inc. Common Stock | $49.0m | $7.39 | 0.0% | 2.0K |